.png)
.png)
Consilium Strategic Communications Advises Hyloris Pharmaceuticals on its Successful Initial Public Offering
London, 3 July 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is delighted to have advised on the successful initial public offering (IPO) of Hyloris Pharmaceuticals SA on Euronext Brussels. The offering raised EUR 62 million which could be increased to EUR 71 million if the overallotment is fully exercised.
Hyloris Pharmaceuticals is based in Liège, Belgium, and is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. By developing proprietary products, the company believes it offers significant advantages compared to currently available alternatives.
The Consilium team was led by Amber Fennell and supported by Chris Welsh, Ashley Tapp, Lucy Featherstone, Carina Jurs, Alex Bridge and Taiana De Ruyck Soares in Belgium. Consilium continues to advise the company on its financial communications and investor relations as a publicly listed company. KBC Securities and Kempen & Co acted as Joint Global Coordinators and Joint Bookrunners in the offering.
Funds raised from the IPO will be used for the development of Hyloris’ existing portfolio of product candidates, the establishment of a commercial team in the United States for its IV Cardiovascular portfolio, to fund the expansion of the pipeline both internally and through business development opportunities, and for general corporate purposes.
Commenting on the successful IPO of Hyloris Pharmaceuticals, Amber Fennell, Partner and Co-Founder of Consilium Strategic Communications, said: “We are delighted to have supported Hyloris through its successful listing on Euronext Brussels and to have assisted Stijn and his team in navigating some of the challenges of communicating with investors during the COVID-19 pandemic. We look forward to continuing to support the business as they commence their journey as a listed company.”
Stijn Van Rompay, Chief Executive Officer at Hyloris Pharmaceuticals, said: “We are grateful for the strong level of support and guidance provided by Consilium throughout the IPO process. The Consilium team has been a huge support in providing us with professional and agile advice, and the team at Hyloris looks forward to continuing our work with Consilium as we establish the company on Euronext Brussels.”
-ENDS-
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.
About Hyloris Pharmaceuticals SA
Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris’ portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with its partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across its wider portfolio. Read more at www.hyloris.com. Hyloris stands for “high yield, lower risk” and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.